Ben Bernanke's spreading his magic around the Dow Jones Industrial Average (DJINDICES: ^DJI ) today. The index has taken another triple-digit leap on quantitative-easing hopes. The Federal Reserve chairman didn't say much about the end of economic stimulus yesterday, nor did the central bank's release of minutes indicate a firm plan to taper easing anytime soon. That's been enough to fuel momentum on the markets: The Dow has taken off by more than 170 points as of 2:25 p.m. EDT, and nearly every stock on the index is in the green. Let's check out the big stories of the day.
Disney paces the Dow's gains
Disney's (NYSE: DIS ) taking advantage of the stimulus-fueled day of gains in a big way, with shares up 2.7% so far to rank among the Dow's top stocks. Investors are looking past the company's big-budget sales flop The Lone Ranger, which has been destroyed by competing films at the box office so far. It's safe to say the film won't be earning back its reported $250 million budget after grossing less than $30 million domestically in its opening weekend.
Top Managed Healthcare Companies To Watch In Right Now: Federal Resources Investment Group Inc (FED)
Federal Resources Investment Group Inc.( FED) is a Philippines-based holding company engaged. The Company�� primary activities were to invest in, purchase, or otherwise dispose of real and personal property of every kind and description, including shares of stock, bonds, debentures, notes, evidences of indebtedness, and other securities or obligations of any corporation or corporations, association and associations, domestic or foreign. Prior to its change in primary purpose, the Company was previously engaged in the manufacture, marketing and distribution of various adhesives and sealants, contact cement, wood glues, epoxies, coating, and other specialty products, and other chemicals for hardware, construction, do-it-yourself and other applications. The Company�� operating segments include PVC Resins and Sealants, Coatings and adhesives. The Company is still in the process of winding up its manufacturing and trading operations and selling its remaining inventories. Advisors' Opinion:- [By Canadian Value]
Nearly all emerging markets took a hit this summer amid speculation the US Federal Reserve Bank (Fed) would soon begin ��apering��its prolonged asset purchase plan, which had pumped large amounts of liquidity into the markets globally. When you hear about this ��apering��of the Fed�� $85 billion monthly bond purchases, it�� important to understand the facts. Tapering isn�� the same as tightening. The Fed-fueled liquidity already pumped in is still working through the system. Additionally, Japan and other global central banks are printing money, adding to the pot.
- [By Canadian Value]
I think too many investors have failed to put those events and developments in the proper context. Rather, they have come to the conclusion that emerging markets are finished, particularly, they say, as the US Federal Reserve (Fed) is expected to turn off the money tap, depriving emerging markets of needed liquidity to protect their weakening currencies and pay their debts. For the time being, the Fed has decided to keep the tap flowing, removing one immediate investor fear. But I think there are also other reasons why investors who doubt the emerging markets��story need better context.
Top Managed Healthcare Companies To Watch In Right Now: ICU Medical Inc.(ICUI)
ICU Medical, Inc. engages in the development, manufacture, and sale of medical technologies used in infusion therapy, oncology, and critical care applications. The company?s product line includes custom infusion systems, closed delivery systems for hazardous drugs, needleless infusion connectors, catheters, and cardiac monitoring systems. Its products enhance patient outcomes by preventing bloodstream infections, protecting healthcare workers and patients from exposure to infectious diseases or hazardous drugs, and monitoring the cardiac output of critical care patients. The company offers intravenous (I.V.) therapy lines consisting of a tube running from a bottle or plastic bag containing an I.V. solution to a catheter inserted in a patient?s vein for use in hospitals and ambulatory clinics; CLAVE product, a needleless I.V. connection device, which would be used with conventional peripheral or central vascular access systems for venous and arterial applications; custom infusion sets. It also provides critical care products that monitor vital signs and specific physiological functions of key organ systems, including disposable pressure-sensing devices, blood sampling systems, angiography kits, sensory catheters, pulmonary artery thermodilution catheters, and multi-lumen central venous catheters. In addition, the company provides TEGO for use in dialysis; a line of oncology products, including Spiros male luer connector device; the Genie vial access device; and custom I.V sets and ancillary products for chemotherapy. ICU Medical, Inc. sells its products to medical product manufacturers and independent medical supply distributors, as well as directly to the end customers worldwide. The company was founded in 1984 and is headquartered in San Clemente, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of ICU Medical (NASDAQ: ICUI ) �-- a medical device maker in the fields of infusion therapy, oncology, and critical care -- soared as much as 17% on a report that the company could be exploring a sale.
- [By Seth Jayson]
ICU Medical (Nasdaq: ICUI ) is expected to report Q2 earnings around July 16. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ICU Medical's revenues will increase 8.0% and EPS will expand 4.8%. - [By CRWE]
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, reported that Company management will be presenting at the UBS Global Life Sciences Conference to be held on September 19-20, 2012, at the Grand Hyatt Hotel, New York.
10 Best Warren Buffett Stocks To Own Right Now: Tranzbyte Corp (ERBB)
The Tranzbyte Corporation, incorporated on November 12, 1998, is a driving force behind Altitude Organic Corporation, One Bode, The YO! Debit Card, and ProximaRF. Altitude Organic Corporation is a medical marijuana dispensary brand. It has developed retailing, branding, and commercial cultivating strategies in conjunction with its licensed medical marijuana retail dispensaries operating under the Altitude Organic Medicine brand name.
Tranzbyte houses the technology division, which is engaged in the sale of its optical media enhancement products to customers in the United States and Asia. Products in the Tranzbyte division include FLASHAlbum and FlixStix technologies that enable distributors of optical media (compact discs, digital video discs, etc.) to consolidate the features of each medium onto a single content-protected universal serial bus (USB) flash drive. One Bode has created an assortment of products focusing on plant-based nutrients and enzymes. Applied radio frequency identification (RFID) and its operating subsidiaries (www.proximarf.com), have a portfolio of RFID reader, sensor tag and data logging products.
Advisors' Opinion:- [By Bryan Murphy]
Though they've been lumped into the same category as Medical Marijuana Inc. (OTCMKTS:MJNA) and Tranzbyte Corp. (OTCMKTS:ERBB), names like Nuvilex Inc. (OTCMKTS:NVLX) and Growlife Inc. (OTCBB:PHOT) aren't actually marijuana stocks. Granted, PHOT and ERBB shareholders will benefit from the advent of legalized marijuana (and hemp) as much as shareholders of ERBB - a grower and dispenser - and MJNA shareholders will. But, in some way they're safer and more stable because they're not directly in the line of fire of potential regulation... or better-enforced regulation at the federal level. Indeed, there are several stocks that are circumventing the risk inherent with marijuana stocks, because they're not marijuana stocks at all. They are, in no particular order....
Top Managed Healthcare Companies To Watch In Right Now: GenMark Diagnostics Inc.(GNMK)
GenMark Diagnostics, Inc. operates as a molecular diagnostics company primarily in the United States. It focuses on the development and commercialization of multiplexed molecular diagnostic testing systems for the detection and measurement of DNA and RNA targets used in the treatment of patients. The company?s products comprise eSensor XT-8 system, an automated molecular diagnostic system, which enable reference laboratories and hospitals to perform molecular diagnostic tests; and eSensor XT-8 Cartridge that utilizes a microfluidic system to accelerate target binding and enhance time to result. It also offers IVD tests, including eSensor cystic fibrosis genotyping test, eSensor thrombophilia risk test, and eSensor warfarin sensitivity test. The company?s other multiplexed molecular diagnostic tests pipeline under development comprise eSensor 2C19 test for the multiplexed detection and genotyping of various alleles of the cytochrome P450 (CYP450) 2C19 gene locus; eSensor respiratory viral panel, a nucleic acid multiplex test for the simultaneous detection and identification of multiple respiratory virus nucleic acids and mutations that confer resistance of Influenza A to the anti-viral drug Oseltamivir (Tamiflu); and eSensor KRAS/BRAF test for the multiplexed detection and genotyping of 12 mutations in codons 12 and 13 of KRAS and the V600E mutation in BRAF. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of GenMark Diagnostics (NASDAQ: GNMK ) , a molecular diagnostics company, slumped as much as 10% after updating its full-year revenue guidance after the bell last night.
- [By Roberto Pedone]
GenMark Diagnostics (GNMK) is a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the U.S. This stock closed up 1.7% to $9.89 in Tuesday's trading session.
Tuesday's Range: $9.24-$9.95
52-Week Range: $6.38-$16.00
Thursday's Volume: 562,000
Three-Month Average Volume: 385,008From a technical perspective, GNMK bounced modestly higher here with above-average volume. This stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $8.75 on the downside and $10.71 on the upside. This bounce is starting to push GNMK within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern. That breakout will hit if GNMK manages to clear some near-term overhead resistance levels at $10.04 to $10.50 and then once it takes out more resistance at $10.71 with high volume.
Traders should now look for long-biased trades in GNMK as long as it's trending above Tuesday's low of $9.24 or around $9 and then once it sustains a move or close above those breakout levels with volume that hits near or above 385,008 shares. If that breakout triggers soon, then GNMK will set up to re-test or possibly take out its next major overhead resistance levels at $12 to $13.50.
Top Managed Healthcare Companies To Watch In Right Now: A. Schulman Inc.(SHLM)
A. Schulman, Inc. supplies plastic compounds and resins for packaging, consumer products, industrial, and automotive applications. The company offers additive compounds, custom color concentrates for film and molding, carbon black color concentrates, white color concentrates, additive compounds for polyester resins and special pearl effects, antistatic concentrates, and masterbatch for the production of synthetic paper. Its products also include engineered plastics, such as thermoplastic elastomers and vulcanizates, filled and unfilled nylon and PBT compounds, nylon/ABS alloys, formulated ionomer compounds, thermoplastic ionomer resins, flame-retardant thermoplastic compounds and concentrates, polypropylene, polyethylene, EVA compounds, thermoplastic olefins, flexible thermoplastic PVC compounds, high-quality PVC compounds, PVC-based thermoplastic elastomers, and low-gloss PVC thermoplastic elastomers for industrial packaging, appliances, electrical connectors, power tools , recreational items, and lawn and garden equipments. In addition, the company provides custom color and specialty compound powders, rotational molding process compounds, cross-linkable resin used in rotational molding, high heat-distortion temperature materials, and thermoplastic powders, as well as provides jet milling services used for products requiring very fine particle size, such as additives for printing ink, adhesives, waxes, and cosmetics; and cryogenic milling services for heat sensitive materials. Further, it buys, repackages, and re-sells polymers for various processing types comprising injection molding, blow molding, thermoforming, and extrusion, as well as provides tolling services. The company operates in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. A. Schulman, Inc. was founded in 1928 and is headquartered in Akron, Ohio.
Advisors' Opinion:- [By Marc Bastow]
Plastic compounds and resins manufacturer A. Schulman (SHLM) raised its quarterly dividend 3% to 20 cents per share, payable Nov. 4 to shareholders of record as of Oct. 28.
SHLM Dividend Yield: 2.51% - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on A. Schulman (Nasdaq: SHLM ) , whose recent revenue and earnings are plotted below. - [By Jeremy Bowman]
What: Shares of A. Schulman (NASDAQ: SHLM ) were getting squashed today, falling as much as 14% after the plastics-maker turned in a subpar quarter.
- [By Rick Munarriz]
Monday
The first trading day of the week, month, and quarter kicks off with A. Schulman (NASDAQ: SHLM ) posting quarterly results. The provider of plastic compounds and resin may not be toiling away in a very glitzy industry, but results matter. A. Schulman has been able to push through three consecutive years of higher dividend rates as consistent growth continues.
No comments:
Post a Comment